Topic Hub
24 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 24 of 24 clinical reviews.
A comprehensive clinical review of flibanserin (Addyi) use in women with autoimmune conditions, covering pharmacology, drug interactions, trial data, and prescribing guidance for HSDD in this population.
Read clinical reviewDoes flibanserin (Addyi) affect appetite or food cravings? A physician-reviewed deep dive into the clinical trial data, proposed mechanisms, and what patients and prescribers need to know.
Read clinical reviewA physician-level review of flibanserin (Addyi) and bone health. Covers pharmacology, estrogen-pathway interactions, clinical trial data, and monitoring guidance for prescribers and patients.
Read clinical reviewA clinician-level review of flibanserin (Addyi) and cancer risk signals: preclinical data, postmarketing surveillance, pharmacology, and what prescribers and patients need to know.
Read clinical reviewA physician-reviewed deep dive into flibanserin (Addyi) cardiovascular safety data, including hypotension, syncope, drug interactions, and long-term heart risk. Includes BEGONIA trial data, FDA REMS requirements, and clinical management guidance.
Read clinical reviewA physician-reviewed deep dive into how flibanserin (Addyi) affects cognitive function, CNS processing, and daily performance, with primary-literature citations, real trial data, and clinical guidance for prescribers and patients.
Read clinical reviewA physician-reviewed comparison of compounded flibanserin vs brand-name Addyi for HSDD, covering pharmacology, clinical trial data, safety, cost, and how to choose.
Read clinical reviewA GRADE-level review of flibanserin (Addyi) for hypoactive sexual desire disorder: trial data, effect sizes, safety signals, and what board-certified clinicians need to know before prescribing.
Read clinical reviewDoes flibanserin (Addyi) cause hair loss or skin changes? A physician-reviewed breakdown of the clinical evidence, mechanism, trial data, and what patients should monitor.
Read clinical reviewA clinical deep-dive into how flibanserin (Addyi) affects liver function, including enzyme elevations seen in trials, the FDA hepatotoxicity warning, alcohol interaction mechanisms, and monitoring protocols for prescribers.
Read clinical reviewA physician-reviewed deep dive into how flibanserin (Addyi) affects mood, anxiety, depression risk, and CNS function in premenopausal women with HSDD, with primary-literature citations throughout.
Read clinical reviewA physician-reviewed deep dive into how flibanserin (Addyi) is metabolized, its CYP3A4/CYP2C19 pathways, effects on energy expenditure, and what clinicians and patients need to know about drug interactions and dosing.
Read clinical reviewA clinician-level review of flibanserin (Addyi) dosing, the evidence base for microdosing approaches, REMS requirements, alcohol interaction pharmacology, and what off-label dose adjustments are supported by current literature.
Read clinical reviewA comprehensive clinical guide to flibanserin (Addyi) and muscle preservation strategies for premenopausal women with HSDD, covering pharmacology, drug interactions, lifestyle co-management, and evidence-based protocols.
Read clinical reviewFlibanserin (Addyi) stopped working or never worked? This MD-level guide covers every evidence-based reason for plateau and non-response, with dosing strategies, drug interactions, and when to switch therapies.
Read clinical reviewFlibanserin (Addyi) after bariatric surgery presents unique pharmacokinetic and safety challenges. This clinical guide covers altered drug absorption, alcohol interaction risks, dosing considerations, and when to refer.
Read clinical reviewA physician-reviewed, evidence-based guide to flibanserin (Addyi) discontinuation. Learn whether rebound HSDD occurs after stopping, what withdrawal symptoms are reported, and how to taper safely.
Read clinical reviewA clinician-level review of flibanserin (Addyi) and kidney safety: pharmacokinetics, renal dosing, drug interactions, and what current evidence says about renal protection versus renal risk.
Read clinical reviewComplete clinical guidance on restarting flibanserin (Addyi) after acute illness, including dose re-titration, drug interaction reassessment, and safety monitoring for premenopausal women with HSDD.
Read clinical reviewA clinical deep-dive into flibanserin (Addyi) seasonal use considerations, including alcohol interaction risks, circadian and mood-related factors, dosing logistics, and how to counsel patients year-round.
Read clinical reviewA physician-reviewed deep dive into how flibanserin (Addyi) affects sexual function in premenopausal women with HSDD, covering trial data, mechanisms, dosing, and real-world outcomes.
Read clinical reviewFlibanserin (Addyi) alters REM sleep, slow-wave sleep, and next-day alertness. Learn the clinical evidence, FDA risk mitigation, and practical dosing guidance.
Read clinical reviewA physician-reviewed guide to adjusting flibanserin (Addyi) dosing during travel, jet lag, time-zone shifts, and irregular sleep schedules, with primary-literature citations and clinical decision frameworks.
Read clinical reviewA physician-reviewed, week-by-week guide to what happens during your first month on Addyi (flibanserin 100 mg) for HSDD, including clinical trial data, dosing, side effects, and realistic timelines.
Read clinical review